Comparative Pharmacology
Head-to-head clinical analysis: HEAD SHOULDERS CONDITIONER versus TERCONAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEAD SHOULDERS CONDITIONER versus TERCONAZOLE.
HEAD & SHOULDERS CONDITIONER vs TERCONAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Not applicable; this is a cosmetic conditioner. No pharmacological mechanism.
Terconazole is a triazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This disrupts membrane integrity and function.
Not applicable. Head & Shoulders Conditioner is a cosmetic product for external use on hair and scalp; no systemic dosing.
Intravaginal cream (0.4%, 0.8%): one applicatorful (approximately 5 g) intravaginally once daily at bedtime for 7 days; vaginal suppository (80 mg): one suppository intravaginally once daily at bedtime for 3 days.
None Documented
None Documented
Clinical Note
moderateTerconazole + Tranilast
"The risk or severity of adverse effects can be increased when Terconazole is combined with Tranilast."
Clinical Note
moderateTerconazole + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Terconazole is combined with Tolfenamic acid."
Clinical Note
moderateTerconazole + Nimesulide
"The risk or severity of adverse effects can be increased when Terconazole is combined with Nimesulide."
Clinical Note
moderateTerconazole + Risedronic acid
Not applicable for systemic elimination; local retention on hair/scalp lasts until next wash (typically 24-48 hours).
Terminal elimination half-life is approximately 25-37 hours, allowing once-daily dosing for vaginal infections.
Renal (urine): <1% unchanged; biliary/fecal: <1% as parent compound; majority remains on hair/scalp and is removed via washing and shedding. Systemic absorption negligible.
Primarily hepatic metabolism with biliary excretion; approximately 60-80% of the dose is excreted in feces as metabolites, and about 20% in urine mostly as inactive metabolites.
Category C
Category A/B
Antifungal/Antidandruff
Antifungal
"The risk or severity of adverse effects can be increased when Terconazole is combined with Risedronic acid."